Jennifer B Lai1,2, Maxwell A Witt1, Mary Patricia Pauly2, Joanna Ready2, Michael Allerton1, Suk Seo2, David J Witt3. 1. Division of Infectious Diseases, Kaiser Permanente, 99 Montecillo Rd, Northern California Region, San Rafael, CA, 94903, USA. 2. Division of Gastroenterology, Kaiser Permanente, Northern California Region, San Rafael, CA, USA. 3. Division of Infectious Diseases, Kaiser Permanente, 99 Montecillo Rd, Northern California Region, San Rafael, CA, 94903, USA. david.j.witt@kp.org.
Abstract
BACKGROUND: Second-generation direct-acting antiviral agents are integral to treatment of hepatitis C (HCV) infection. Eight-week courses of ledipasvir/sofosbuvir (LDV/SOF) have been supported in some studies, but data are limited on efficacy in real-world use. Controversy exists regarding applicability of clinical trials to real-world effectiveness. We report virologic responses of patients with HCV genotype 1 infection receiving LDV/SOF for 8 or 12 weeks in a large integrated healthcare system. METHODS: All patients receiving LDV/SOF, without ribavirin, were identified from pharmacy records, and outcomes are reported. Only treatment-naïve patients without evidence of cirrhosis and hepatitis C viral load less than 6 million IU/ml were candidates for 8-week therapy. Treatment was at clinician discretion, but delivered by a multidisciplinary team and reviewed for appropriateness and adherence to these criteria by one of the authors, all experienced in hepatitis C treatment. Sustained viral response at 12 weeks (SVR 12) was contrasted between those receiving 8 and those receiving 12 weeks of treatment. RESULTS: Completed prescriptions for LDV/SOF, without ribavirin, as of 30 September 2015 were identified in 1021 patients. Five patients discontinued therapy due to medical reasons and 35 had incomplete follow-up viral load data, thus there were 981 evaluable patients: 377 treated for 8 weeks and 604 treated for 12 weeks. SVR 12 was virtually identical at 93.6 and 93.5%, respectively. Baseline characteristics differed between the two groups, as only treatment-naïve, non-cirrhotic, non-HIV-infected patients were eligible for an 8-week course of therapy. CONCLUSIONS: Eight-week courses of LDV/SOF are comparable to 12-week courses in real-world use among selected patients supported by a multidisciplinary team.
BACKGROUND: Second-generation direct-acting antiviral agents are integral to treatment of hepatitis C (HCV) infection. Eight-week courses of ledipasvir/sofosbuvir (LDV/SOF) have been supported in some studies, but data are limited on efficacy in real-world use. Controversy exists regarding applicability of clinical trials to real-world effectiveness. We report virologic responses of patients with HCV genotype 1 infection receiving LDV/SOF for 8 or 12 weeks in a large integrated healthcare system. METHODS: All patients receiving LDV/SOF, without ribavirin, were identified from pharmacy records, and outcomes are reported. Only treatment-naïve patients without evidence of cirrhosis and hepatitis C viral load less than 6 million IU/ml were candidates for 8-week therapy. Treatment was at clinician discretion, but delivered by a multidisciplinary team and reviewed for appropriateness and adherence to these criteria by one of the authors, all experienced in hepatitis C treatment. Sustained viral response at 12 weeks (SVR 12) was contrasted between those receiving 8 and those receiving 12 weeks of treatment. RESULTS: Completed prescriptions for LDV/SOF, without ribavirin, as of 30 September 2015 were identified in 1021 patients. Five patients discontinued therapy due to medical reasons and 35 had incomplete follow-up viral load data, thus there were 981 evaluable patients: 377 treated for 8 weeks and 604 treated for 12 weeks. SVR 12 was virtually identical at 93.6 and 93.5%, respectively. Baseline characteristics differed between the two groups, as only treatment-naïve, non-cirrhotic, non-HIV-infectedpatients were eligible for an 8-week course of therapy. CONCLUSIONS: Eight-week courses of LDV/SOF are comparable to 12-week courses in real-world use among selected patients supported by a multidisciplinary team.
Authors: Linda S Elting; Catherine Cooksley; B Nebiyou Bekele; Michael Frumovitz; Elenir B C Avritscher; Charlotte Sun; Diane C Bodurka Journal: Cancer Date: 2006-06-01 Impact factor: 6.860
Authors: Michael A Horberg; Leo B Hurley; William J Towner; Michael W Allerton; Beth T Tang; Sheryl L Catz; Michael J Silverberg; Charles P Quesenberry Journal: J Acquir Immune Defic Syndr Date: 2012-06-01 Impact factor: 3.731
Authors: Patrick Ingiliz; Stefan Christensen; Torben Kimhofer; Dietrich Hueppe; Thomas Lutz; Knud Schewe; Heiner Busch; Günther Schmutz; Malte H Wehmeyer; Christoph Boesecke; Karl-Georg Simon; Florian Berger; Jürgen K Rockstroh; Julian Schulze zur Wiesch; Axel Baumgarten; Stefan Mauss Journal: Clin Infect Dis Date: 2016-08-17 Impact factor: 9.079
Authors: Norah A Terrault; Stefan Zeuzem; Adrian M Di Bisceglie; Joseph K Lim; Paul J Pockros; Lynn M Frazier; Alexander Kuo; Anna S Lok; Mitchell L Shiffman; Ziv Ben Ari; Lucy Akushevich; Monika Vainorius; Mark S Sulkowski; Michael W Fried; David R Nelson Journal: Gastroenterology Date: 2016-08-24 Impact factor: 22.682
Authors: Eric Lawitz; Fred F Poordad; Phillip S Pang; Robert H Hyland; Xiao Ding; Hongmei Mo; William T Symonds; John G McHutchison; Fernando E Membreno Journal: Lancet Date: 2013-11-05 Impact factor: 79.321
Authors: Michael A Horberg; Leo B Hurley; William J Towner; Michael W Allerton; Beth T Tang; Sheryl L Catz; Michael J Silverberg; Charles P Quesenberry Journal: HIV AIDS (Auckl) Date: 2012-08-15
Authors: Julius M Wilder; Lennox J Jeffers; Natarajan Ravendhran; Mitchell L Shiffman; John Poulos; Mark S Sulkowski; Norman Gitlin; Kimberly Workowski; Yanni Zhu; Jenny C Yang; Phillip S Pang; John G McHutchison; Andrew J Muir; Charles Howell; Kris Kowdley; Nezam Afdhal; K Rajender Reddy Journal: Hepatology Date: 2015-12-18 Impact factor: 17.425
Authors: S S Solomon; D Boon; S Saravanan; A K Srikrishnan; C K Vasudevan; P Balakrishnan; D Persaud; S C Ray; S Mehta; S H Mehta Journal: Virusdisease Date: 2019-12-07
Authors: Julia L Marcus; Michael J Silverberg; Jennifer O Lam; Leo B Hurley; Jennifer B Lai; Varun Saxena; Suk Seo; Scott Chamberland; Charles P Quesenberry; Jamila H Champsi; Joanna Ready; Elizabeth Y Chiao Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-09-28 Impact factor: 4.090
Authors: David A Wohl; Andrew G Allmon; Donna Evon; Christopher Hurt; Sarah Ailleen Reifeis; Harsha Thirumurthy; Becky Straub; Angela Edwards; Katie R Mollan Journal: Open Forum Infect Dis Date: 2017-05-05 Impact factor: 3.835
Authors: Rachel A Stewart; Brooke R MacDonald; Tzu-Chun Chu; Jonathan D Moore; Esther O Fasanmi; Rohit P Ojha Journal: Dig Dis Sci Date: 2018-07-16 Impact factor: 3.199
Authors: Peter Buggisch; Karsten Wursthorn; Albrecht Stoehr; Petar K Atanasov; Romain Supiot; Janet Lee; Jie Ting; Joerg Petersen Journal: PLoS One Date: 2019-04-04 Impact factor: 3.240
Authors: Massimo Giuseppe Colombo; Erkin Isakovich Musabaev; Umed Yusupovich Ismailov; Igor A Zaytsev; Alexander V Nersesov; Igor Anatoliyevich Anastasiy; Igor Alexandrovich Karpov; Olga A Golubovska; Kulpash S Kaliaskarova; Ravishankar Ac; Sanjay Hadigal Journal: World J Gastroenterol Date: 2019-08-07 Impact factor: 5.742